Search

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Eyecare education in times of COVID-19

A collaboration between the German Committee for the Prevention of Blindness (DKVB), Rukwa regional government in Tanzania and the University of St Andrews Global Health Team successfully delivered a hybrid teaching programme for ophthalmic nurses in Sumbawanga, south west Tanzania,...

ChatGPT cannot pass FRCOphth examinations: implications for ophthalmology and large language model artificial intelligence

Large language models are generating a lot of hype for artificial intelligence, but can they assist patients and practitioners in ophthalmology? Introduction Deep learning (DL) has emerged in ophthalmology as an exciting form of artificial intelligence (AI) most commonly applied...

Observership in Dar es Salaam

In this report, both authors present their personal experiences of an observership at the Comprehensive Community Based Rehabilitation in Tanzania (CCBRT) Hospital, a large regional teaching hospital located in Dar es Salaam, with a particular focus on resource management, attitudes...

The Global Vision Database

The overall goal of the Global Vision Database (GVD) [1] is to develop and deploy new and improved evidence on the prevalence of blindness and vision impairment (VI) globally. It is a repository which allows us to assess the causes...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

See sweet to C-suite: Imran Rahman

See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...